KRAS and colorectal cancer: The data presented here substantiate the activity of anti-EGFR monoclonal antibodies in advanced colorectal cancer, but also show the need for selection strategies beyond the current reliance on KRAS. Rapid independent validation or refutation of the PICCOLO findings is feasible using existing clinical trial biobanks.